08:27 AM EST, 11/04/2025 (MT Newswires) -- Harmony Biosciences ( HRMY ) reported Q3 adjusted net income Tuesday of $1.08 per diluted share, up from $0.99 a year earlier.

Analysts polled by FactSet expected $1.01.

Revenue for the quarter ended Sept. 30 was $239.5 million, up from $186 million a year earlier.

Analysts surveyed by FactSet expected $226.9 million.

The company raised its full-year 2025 net product revenue guidance to a range of $845 million to $865 million from the previous guidance of $820 million to $860 million. Analysts polled by FactSet expect $849.5 million.